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13.04.001Abstract The involvement of aldo–keto reductases (AKRs) in tumorigenesis is widely reported,
but their roles in the pathological process are not generally recognized due to inconsistent measure-
ments of their expression. To overcome this problem, we simultaneously employed real-time PCR
to examine gene expression and multiple reaction monitoring (MRM) of mass spectrometry (MS) to
examine the protein expression of AKRs in ﬁve different hepatic cell lines. These include one rela-
tively normal hepatic cell line, L-02, and four hepatocellular carcinoma (HCC) cell lines, HepG2,
HuH7, BEL7402 and SMMC7721. The results of real-time PCR showed that expression of genes
encoding the AKR1C family members rather than AKR1A and AKR1B was associated with
tumor, and most of genes encoding AKRs were highly expressed in HuH7. Similar observations
were obtained through MRM. Different from HuH7, the protein abundance of AKR1A and
AKR1B was relatively consistent among the other four hepatic cell lines, while protein expression
of AKR1C varied signiﬁcantly compared to L-02. Therefore, we conclude that the abundant distri-
bution of AKR1C proteins is likely to be associated with liver tumorigenesis, and the AKR expres-
sion status in HuH7 is completely different from other liver cancer cell lines. This study, for the ﬁrst
time, provided both overall and quantitative information regarding the expression of AKRs at both
mRNA and protein levels in hepatic cell lines. Our observations put the previous use of AKRs as a
biomarker into question since it is only consistent with our data from HuH7. Furthermore, the data
presented herein demonstrated that quantitative evaluation and comparisons within a protein fam-
ily at both mRNA and protein levels were feasible using current techniques.eijing Institute of Genomics,
tics Society of China.
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Aldo–keto reductases (AKRs), which include approximately
160 members, are a protein superfamily that is widely distrib-
uted from prokaryotes to eukaryotes [1–3]. Most AKRs are
generally believed to be the pivotal enzymes for the detoxiﬁca-
tion of reactive aldehydes [4]. To date, 13 AKR proteins have
been identiﬁed in humans, including AKR1A1 (aldehydecademy of Sciences and Genetics Society of China. Production and hosting
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AKR1C1–1C4 (hydroxysteroid dehydrogenase, HSD),
AKR1D1 (D4-3-ketosteroid-5b-reductase), AKR6A3,
AKR6A5, AKR6A9 (Kvb), AKR7A2 and AKR7A3 (aﬂa-
toxin aldehyde reductase) [4,5]. Over recent years, it has be-
come increasingly clear that many human AKRs are
intimately linked with cancer biology. Expression of some
AKR1 members that may be induced by oxidative stress and
participate in different signaling pathways of cell proliferation
was increased in different types of cancer. For example, expres-
sion of AKR1B10 and AKR1C3 increased the risk of cancer in
the target organ through the retinal reductase activity, thus
leading to reduction in retinoic acid (RA) biosynthesis [6].
AKR7 family is involved in the metabolism of aﬂatoxin [7],
which is a well-known carcinogen for the liver. Despite these
studies, the signiﬁcance of the involvement of AKRs in can-
cers, however, is not yet fully elucidated. Moreover, which
AKR member is speciﬁcally related with cancer type is still
inconclusive. For instance, overexpression of AKR1B10 was
considered as a novel biomarker for non-small cell lung carci-
noma (NSCLC) [8]. The association of AKR1B10 in NSCLC
with smoking was established by microarray analysis and con-
ﬁrmed by RT-PCR, immunobloting and immunohistochemis-
try (IHC) in paired samples of squamous cell carcinomas
(SCC) and noncancerous tissues [8–11]. However, the associa-
tion did not gain strong support from other large screenings in
genomics, transcriptomics, and proteomics [12]. Lin et al. re-
ported that, AKR1C3 was consistently overexpressed in ductal
carcinoma tissues of breast cancer in situ using IHC [13]. Ji
et al. took a similar strategy but came to the opposite results
that selective loss of AKR1C1 and AKR1C2 was found in
24 paired breast cancer tissues, whereas AKR1C3 was only
minimally affected in the same samples [14]. Besides AKR1B10
and AKR1C3, abnormal expression of other AKR members,
such as AKR1A1 [15], AKR1B1 [16,17], AKR1C1, AKR1C2
and AKR1C4 [14,18–29], was detected in various cancer tis-
sues or cells. However, employment of different approaches
in different studies has led to conﬂicting results, which are
not easily further cross validated by other approaches or labo-
ratories due to the different samples examined, expression lev-
els and even different cut-offs.
The controversial observations regarding AKRs and cancer
necessitate the development of an approach to accurately eval-
uate the AKR abundances in cells and tissues. Fundamentally,
three questions ought to be addressed. First of all, most previ-
ous studies on AKR gene expression have only reported one or
several AKR members, there lacks general understanding of
the expression proﬁle for all the AKR family members. As
many AKR enzymes convert the similar substrates following
the same catalytic mechanism in vivo [30], it is likely that the
protein abundances would compensate for each other [31,32].
Therefore, focusing on individual AKRs rather than the family
has probably led to misinterpretation of the biological signiﬁ-
cance of the expression status of AKRs in cancers. Secondly,
the conﬂicting conclusions regarding AKR expression were of-
ten drawn from different measurements, at mRNA or protein
level. As mRNA abundance is not closely and linearly corre-
lated with protein abundance for many genes, conclusion only
derived from the mRNA or protein assay may lead to a dis-
torted view of expression. Hence, monitoring the AKR expres-
sion status in cells or tissues at both mRNA and protein levels
should be more appropriate. Thirdly, for global screening ofthe tumor-associated genes, traditional techniques such as
DNA/RNA array and protein proﬁling are often lacking in
accurate quantitative information, such that screening data
are not always comparable with targeting data in biomarker
discovery. How to quantitatively evaluate the AKR expression
is another key issue required to clarify the controversial argu-
ment of the relationship of AKRs with cancers. Therefore, we
carried out the global evaluation of the AKR expression status
in cancer cell lines, trying to address the three issues mentioned
above.
Liver is an important organ involved in detoxiﬁcation in the
human body and contains all types of human AKR proteins to
perform such functions. Several investigators reported that the
abnormal expression of AKR proteins in liver tumor tissues or
cells possibly resulted in loss of detoxiﬁcation functions [33,34].
For instance, Cao et al. observed that expression of AKR1A1
remained unchanged while AKR1B1 was overexpressed in
HCC [35]. However, Goh et al. found that expression of
AKR1A1 was decreased, while AKR1B1 did not change signif-
icantly in HCC [36]. Therefore, liver cancer cells or tissues
would be ideal for quantitatively evaluating the AKR
expression status, either to detect the expression of AKR mem-
bers globally or to clarify the argument on the AKR roles in li-
ver cancers. Therefore, four liver cancer cell lines were chosen
to evaluate the global expression of AKRs. The obtained re-
sults were further validated at the protein level using 55 pairs
of HCC samples and adjacent tissues.
In this study, we designed an analysis strategy aiming at
globally and quantitatively to determine the abundance of
individual AKRs at both mRNA and protein in the selected
cell lines. We employed real-time PCR to monitor the expres-
sion of AKR mRNAs and MRM-based MS to detect the
expression of AKR proteins. With calibration and normaliza-
tion, we produced the proﬁles for the abundance distribution
of all the AKR gene products, and demonstrated the correla-
tion of the AKRs and cancer cell lines.Results
Preparation for quantitative evaluation of AKR expression in
hepatic cell lines and tissues
Totally 13 AKRs have been reported in human. These include
10 AKRs with the aldo–keto enzyme activities, such as
AKR1A1, AKR1B1, AKR1B10, AKR1C1–1C4, AKR1D1,
AKR7A2 and AKR7A3, and 3 AKRs without the catalytic
functions, such as AKR6A3, AKR6A5 and AKR6A9. As
detoxiﬁcation by AKRs is believed to be involved in tumori-
genesis and tumor development, the AKR members without
enzymatic activities were not considered in this study. Besides,
there is a high homology in the amino acid sequences of
AKR1C1 and AKR1C2 (approximately 97%) and the high
identity of the two genes makes the measurement at either
mRNA or protein levels technically difﬁcult. These two AKRs
were thus regarded as a single protein product termed as
AKR1C1/1C2 in this study. In total, 9 AKRs were selected
for quantitative evaluation of their expression, including
AKR1A1, AKR1B1, AKR1B10, AKR1C1/1C2, AKR1C3,
AKR1C4, AKR1D1, AKR7A2 and AKR7A3. Each unique
peptide had four qualiﬁed transitions.
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ate for the quantiﬁcation of mRNA and protein abundances,
because they can provide relatively accurate quantitative infor-
mation. During measurements, design of both the real-time
PCR primers and the MRM unique peptides for each AKR
is fundamentally important to clearly distinguish the AKR
members. As a matter of fact, it was not an easy job to select
the primers or peptides in such enzyme family, since these
members share such high sequence homology at either nucleo-
tide or amino acid levels. Primers that are able to amplify the
unique sequences of various AKR genes with a length of 100–
200 bp were synthesized and carefully evaluated for ampliﬁca-
tion in pilot experiments prior to the real-time PCR experi-
ments (sequencing validation was shown in Figure S1).
However, expression of AKR1D1 and AKR7A3 was not de-
tected in our samples (data not shown). In peptide design for
MRM, the similar difﬁculty appeared in selecting multiple un-
ique peptides of AKRs due to the highly homologous amino
acid sequences in AKR proteins. Thus the selection of proper
peptides/transitions was based on the recombinant AKRs
identiﬁed by MS. Using data-independent acquisition to detect
all the digested peptides of each AKR protein in an EMS–EPI
scan (the shotgun scan preformed on QTRAP5500 by a com-
bination of enhanced MS and product ion scans), high quality
MS/MS signals corresponding to the AKR peptides were ac-
quired. Furthermore, according to the criteria for selecting
the MRM peptide, the AKR transitions were predicted with
MRM pilot in MRM–EPI mode (MRM triggered enhanced
product ion scan). Taking into accounts of the scanning results
from EMS–EPI and MRM–EPI upon the AKR recombinant
peptides, numbers of qualiﬁed AKR peptides for MRM were
ﬁnally deﬁned, that is, two unique peptides for AKR1A1,
AKR1B1 and AKR1B10, and single unique peptide for the
remaining AKR1C1/1C2, AKR1C3, AKR1C4 and AKR7A2.
According to our experimental design, it would be valuable
to evaluate the AKR expression not only within cell lines but
also at tissue level. Technically speaking, both techniques,Figure 1 Relative mRNA abundance of each AKR in hepatic cell line
Relative mRNA abundance of each AKR was measured by real-time P
L-02, with four HCC cell lines HepG2, HuH7, BEL7402 and SMM
housekeeping gene ACTB in respective cell lines. The comparison of m
Signiﬁcant differences in abundance are denoted with #, *, q and w, w
respectively. indicates signiﬁcant difference between respective cell lreal-time PCR and MRM, are difﬁcult to use in tissue samples,
whereas IHC is a proper approach to detect the AKRs if the
AKR antibodies are available. Unfortunately, appropriate
antibodies for IHC against the 7 AKRs are not yet commer-
cially available. So we developed the speciﬁc monoclonal anti-
bodies against AKRs by using the full length or truncated
recombinant AKRs as the antigens (Figure S2). Appropriate
monoclonal AKR antibodies were characterized based upon
two criteria: 1) no cross reactions between any AKR recombi-
nant proteins, and 2) single band appeared in Western blot
against the cell lysate (Figure S2).
Quantitative AKR transcriptomes in hepatic cell lines
In all the hepatic cell lines, strong signals were detected for
AKR mRNAs using real-time PCR with actin as the internal
control in triplicate experiments, although the signal was rela-
tively lower in L-02 for AKR1C4. Figure 1 shows the relative
transcript abundance of AKRs in each hepatic cell line. It is
readily noticed that the mRNA abundance of almost AKR
members in HuH7 was dramatically higher than that in the
other hepatic cell lines. In human genome, AKR1A1 and
AKR7A2 are located on chromosome (Chr) 1p, AKR1B1
and AKR1B10 are found on Chr 7q, while all the AKR1Cs
are located on Chr10p. The globally higher AKR transcription
in HuH7 thus implies that there may occur abnormality in
copy numbers of chromosomes in HuH7 cells (see character-
ization of HuH7 in JCRB cell bank), at least for Chr 1, 7
and 10 where AKR genes are located. Of the four hepatic can-
cer cell lines examined in this study, only HuH7 exhibited the
unique features of AKR mRNA abundance. Therefore, we
suspect that whether AKR expression in HuH7 is representa-
tive for hepatic cancer is thus questionable in the ﬁeld. The
mRNA abundant proﬁles presented in Figure 1 indeed con-
tained plentiful information regarding AKR expression status.
Except for HuH7, mRNA abundance for four AKRs remained
relatively stable both in normal and tumor cell lines, followings by real-time PCR
CR in 5 hepatic cell lines, respectively (one relative normal cell line
C7721). The 4Ct values of AKRs were normalized by those of
RNA abundances of the AKRs was achieved by 244Ct method.
hen compared to AKR1A1, AKR1B1, AKR1B10 and AKR1C3,
ines and HuH7. n= 5; P< 0.05.
Figure 2 Relative protein abundance of each AKR in hepatic cell lines
Relative protein abundance of each AKR was measured by MRM in 5 hepatic cell lines, respectively (one relative normal cell line L-02,
with four HCC cell lines HepG2, HuH7, BEL7402 and SMMC7721). The fold changes of AKR1A1 (A), AKR1B1(B), AKR1B10 (C),
AKR1C1/1C2 (D), AKR1C3 (E), AKR1C4 (F) and AKR7A2 (G) protein in four HCC cell lines were calculated, with changes in L-02 set
as 1. n= 4 (except n= 1 for AKR1C4 in BEL7402 and SMMC7721); *indicates signiﬁcant difference compared to L-02 (P< 0.05).
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R7A2 > AKR1B10. Therefore, mRNA abundance distribu-
tion patterns for theses four AKRs in these cell lines are
unlikely to bear any cancer characteristics. However, themRNA abundance distribution of AKR1C displayed different
patterns within the cell lines. mRNA abundance of AKR1C1/
1C2 was lower than that of AKR1C3 in L-02, HepG2 and
BEL7402, while the relative mRNA abundance ratio of
Cancer tissues Adjacent tissues
AKR1B10
AKR1A1
Figure 3 Distribution of AKR1A1 and AKR1B10 protein in HCC
Totally, 55 pairs of HCC and their adjacent tissues were examined. Shown here are representative images for AKR1A1 (upper panel) and
AKR1B10 (lower panel). Staining intensity of AKR1B10 in cancer regions was relative higher than that in adjacent tissues, whereas
AKR1A1 exhibited the opposite trends. All images were taken with 400· magniﬁcation.
234 Genomics Proteomics Bioinformatics 11 (2013) 230–240AKR1C1/1C2 to AKR1C3 in SMMC7721 was in the opposite
direction. Moreover, mRNA abundance of AKR1C4 in all the
tumor cell lines was signiﬁcantly higher than that in L-02. Tak-
ing all together, the transcriptional status of the AKR1C fam-
ily members rather than that of AKR1A and AKR1B may
have tumor-related signiﬁcance. It is interesting to note that
mRNA expression of AKR1B10 was remarkably high in
HuH7 (more than 400 folds than that in L-02, P< 0.05), even
higher than that of AKR1B1. AKR1B1 and AKR1B10 are lo-
cated on Chr 7q35 and 7q33, respectively. Whether the extre-
mely abnormal expression of AKR1B10 could be associated
with the chromosomal position during tumorigenesis remains
to be further explored.
Quantitative AKR proteomes in hepatic cell lines
In most cells, the selected AKR peptides with the correspond-
ing transitions generated high quality MRM signals, which
were satisfactory for accurate quantiﬁcation based upon the
mass differential tags for relative and absolute quantiﬁcation
(mTRAQ) approach. The corresponding peptide signals wereTable 1 IHC results of human AKR monoclonal antibodies
AKR Tissue samples Total No.
AKR1A1 Cancer tissues 55
Adjacent tissues 55
AKR1B10 Cancer tissues 55
Adjacent tissues 55
AKR1C1/1C2 Cancer tissues 55
Adjacent tissues 55
AKR1C3 Cancer tissues 55
Adjacent tissues 55
AKR1C4 Cancer tissues 55
Adjacent tissues 55
Note: Difference in staining between cancer and adjacent tissues was conseasily detected in L-02, HepG2 and SMMC7721 (Table S1).
However, we failed to acquire MRM signals of AKR1C1/
1C2 and AKR1C3 in BEL7402 for unknown reasons,
although mRNA abundance of AKR1C1/1C2 and AKR1C3
in BEL7402 was comparable to that in the other three cell
lines. Therefore, we suspect that some interference in the m/z
range of the AKR1C1/1C2 and AKR1C3 peptides in
BEL7402 may block the generation of the corresponding tran-
sitions. Compared to the other cell lines, HuH7 still showed
quite distinct features in AKR abundance. In particular, the
abundance for AK1B10 and AKR1C1/1C2 was increased sig-
niﬁcantly compared to L-02 (P< 0.05), while that in the other
cell lines was decreased or remained unchanged. The protein
abundance of the other AKRs in HuH7, however, showed dif-
ferent patterns from the abundance of their corresponding
mRNAs. Abundance of AKR mRNAs in HuH7 were globally
higher than that in the other cell lines (Figure 1), whereas
abundance of AKR1A1, AKR1B1 and AKR7A2 proteins in
HuH7 had no signiﬁcant increase (Figure 2). In these cells,
what kind of changes in translation or protein degrada-
tion might be responsible for AKR abundances remains aNegative No. (%) Positive No. (%) P value
37 (67.27%) 18 (32.73%) 0.007
23 (41.82%) 32 (58.18%)
18 (32.73%) 37 (67.27%) 0.007
32 (58.18%) 23 (41.82%)
36 (65.45%) 19 (34.55%) 1.000
36 (65.45%) 19 (34.55%)
22 (40.00%) 33 (60.00%) 0.846
23 (41.82%) 32 (58.18%)
26 (47.27%) 29 (52.73%) 0.126
34 (61.82%) 21 (38.18%)
idered as signiﬁcant with P< 0.05.
Table 2 Correlation analysis of human AKRs with HCC differentiation degree
AKR Staining Total No. Tumor diﬀerentiation degree P value
Low Medium Well
AKR1A1 Negative
37 13 13 11
0.166
Positive
18 8 2 8
AKR1B10 Negative
18 11 2 5
0.037
Positive
37 10 13 14
AKR1C1/1C2 Negative
36 16 11 9
0.121
Positive
19 5 4 10
AKR1C3 Negative
22 7 5 10
0.381
Positive
33 14 10 9
AKR1C4 Negative
26 8 7 11
0.456
Positive
29 13 8 8
Note: Correlation was considered as signiﬁcant with P< 0.05.
Yang L et al / AKR Proﬁling in HCC Cell Lines 235worthwhile question for later investigation. Furthermore,
overexpression of AKR1B10 at both mRNA and protein levels
in HuH7 raised two questions as to why the signals for tran-
script and protein expression were so strong for AKR1B10
and what would be associated with such overexpression.
Abundance distribution of AKR1A1, AKR1B1 and
AKR1B10 was similar in the hepatic cell lines examined except
for HuH7. On the other hand, AKR7A2 expression exhibited
some cell-type dependence. For instance, abundance of
AKR7A2 in SMMC7721 was much higher than that in the
other cell lines. The distribution of the AKR1C protein
abundance was correlated with the cell lines as well. Relative
abundance of AR1C1/1C2 to AKR1C3 showed different pat-
terns in L-02, HepG2, HuH7 and SMMC7721. The protein
abundance of AKR1C4 in L-02 was obviously lower than that
in the tumor cell lines, which is similar to the observation in the
AKR1C4 mRNA abundance. Therefore, if HuH7 is not con-
sidered, the quantitative proteomics results support the conclu-
sion that the abundance distribution of AKR1A and AKR1B
demonstrates the similar pattern in L-02, HepG2, BEL7402
and SMMC7721, while abundance of AKR1C displays a tu-
mor-associated pattern.
Evaluation of the AKR protein expression status in hepatic
tissues
To speciﬁcally examine the expression of respective AKR
proteins, we expressed and puriﬁed 14 recombinant AKR
proteins (in full or partial sequences), which were used as
antigens to generate antibodies against various AKRs. In to-
tal, ﬁve speciﬁc monoclonal AKR antibodies that were pre-
pared in our laboratory, including AKR1A1 S65,
AKR1B10 S2, AKR1C1/1C2 S29, AKR1C3 S8 and
AKR1C4 S34, were shown to be successful as IHC antibod-ies. We collected 55 HCC samples and 55 adjacent tissue
(non-HCC) samples, which included 19 pairs of well-differen-
tiated tissues, 15 pairs of medium-differentiated ones and 21
pairs of low-differentiated ones in the tissue samples, from
HCC patients, each consisting of an HCC tumor samples
and adjacent tissue samples. IHC was performed for these
samples using the aforementioned AKR antibodies. Our re-
sults demonstrated varied staining pattern in tissues with dif-
ferent AKR antibodies (Figure 3). Analysis of the 55 HCC
and 55 non-HCC samples revealed that positive staining for
AKR1A1 appeared in 32.7% of the HCC samples (18 sam-
ples) examined and 58.2% of the non-HCC samples (32 sam-
ples) (Table 1). Similarly, we showed that AKR1B10 was
detected in 67.3% (37 samples) of the tumor tissues and
41.8% of the non-HCC samples (23 samples). Further statis-
tical analysis indicated that differences in IHC signals for
AKR1A1 and AKR1B10 between the tumor and adjacent tis-
sues were signiﬁcant in these paired samples (P< 0.05, Ta-
ble 1), while no signiﬁcant difference was observed for
AKR1C proteins (P> 0.05, Table 1). We then went further
to detect whether the staining for AKR proteins was associ-
ated with the differentiation states of HCC. Our analysis
showed that no signiﬁcant correlation was found for staining
of AKR1A1 and AKR1C1–1C4 proteins and the differentia-
tion stages (P> 0.05, Table 2). However, the heavy staining
of AKR1B10 was signiﬁcantly associated with the differenti-
ation states of HCC, due to the presence of the signiﬁcant
correlation (P= 0.037, Table 2).
Although the controversial results obtained from the AKR
measurements in cells and tissues were somewhat disappoint-
ing, the data are still worthy of further investigation. First of
all, AKRs are important detoxiﬁcation enzymes in the liver
and the relatively high abundances of AKRs are expected in
the normal liver. IHC data in the adjacent tissues are
236 Genomics Proteomics Bioinformatics 11 (2013) 230–240consistent with their important roles under normal conditions.
Thus, the high background expression of AKRs may set the
obstacle to distinguishing small differences in AKRs between
tumor and adjacent tissues with IHC. Secondly, the sample
collection may be another source of experimental errors.
How to get samples with a high percentage of tumor cells is al-
ways challenging. Thirdly, AKRs are expressed in many tis-
sues, including connective tissue and vessels [37]. AKR
detection in a relatively pure cell population (such as a cell line)
is likely different from a mixed cell population (excised
tissues).Discussion
The technical obstacles in quantitative evaluation of AKR
expression status were priority considerations when we initi-
ated this project. There are fewer technical challenges for
quantitative measurement of AKR transcripts, since PCR
products corresponding to the individual AKRs were satisfac-
torily ampliﬁed with properly-designed primers and appropri-
ate PCR conditions for quantiﬁcation. In order to globally
estimate AKR protein abundances, our laboratory has devel-
oped an approach based upon antibody recognition [38].
Using Pan-AKR-P4, an antibody generated in our lab with
high afﬁnity to all the mouse AKR proteins, for 2-DE immu-
noblotting to examine the AKR abundances in mouse liver
and kidney, our semi-quantitative data were in good agree-
ment with other previous reports [39]. This technique is useful
to evaluate the sum abundance of AKRs, nevertheless, it is
useless for globally evaluating and comparing abundance of
individual AKRs. Importantly, antibody-based measurement
of AKRs offers relative limited information in accurate quan-
tiﬁcation. In this study, we utilized the mTRAQ/MRM ap-
proach to quantitatively measure the absolute abundances of
the individual AKRs in hepatic cell lines. MRM measurement
of AKRs in these hepatic cell lines provided relatively accurate
data in protein quantiﬁcation with the acceptable coefﬁcient of
variation values (Figure 2). The absolute quantiﬁcation of
AKRs thus makes it possible to globally and quantitatively
evaluate contribution of various AKRs to different cancer cell
lines. Taken together, both quantitative techniques were estab-
lished to evaluate AKR expression status. Importantly, such
strategy of quantitative evaluation can be potentially applied
to other protein families.
The quantitative data in this study revealed that the
AKR1C members are likely to be associated with hepatic tu-
mor because abundance patterns of AKRs at either mRNA
or protein levels were quite diverse among the cell lines exam-
ined. On the other hand, AKR1A and AKR1B appear to have
a relatively stable abundance in these cell lines. Functional
plasticity of AKR1Cs highlights their ability to modulate theTable 3 Features of the ﬁve hepatic cell lines examined in this study
Cell line Origin Ethnicity/race Age (years)
L-02 Liver Chinese –
HepG2 HCC Caucasian 15
HuH7 HCC Japanese 57
SMMC7721 HCC Chinese 50
BEL7402 HCC Chinese 53levels of active hormones such as androgens, oestrogens and
progestins [25,40–42]. For instance, 20-alpha-hydroxysteroid
is an AKR1C1 substrate, while 3-alpha- and 17-beta-hydroxy-
steroid are oxidized by AKR1C2, AKR1C3 and AKR1C4 [43].
Hormone-dependent tissues require local production of andro-
gens and estrogens to stimulate cell proliferation [25]. Penning
et al. proposed that participation of AKR1Cs in conversion of
hormones and their derivatives may stimulate the growth of
hormone-dependent and -independent prostate and breast can-
cer [25,44,45]. In addition, some investigators found that the
AKR1Cs were correlated with hormone-independent malig-
nancies [20,46]. Figueroa et al. reported that overexpression
of AKR1C3 was a high-risk factor in bladder cancer [47], while
Hsu et al. observed that AKR1C mRNAs were not detected in
the normal lung tissues but were overexpressed in 47% of the
patients with non-small cell lung cancer (NSCLC) [18].
Although many documents indicate that AKR1C proteins play
some roles in tumorigenesis, involvement of AKR1C in liver
cancer is still a new view in the ﬁeld. There is lack of evidence
in the literature to support this hypothesis. IHC data generated
from this study unfortunately did not provide supportive evi-
dence to this hypothesis, due to the contradictory results with
MRM data. More experiments are necessary to solve this ca-
veat, since the quantitative data were generated upon solid
experimental bases, and cross validated at mRNA and protein
levels in cell lines, we could not ﬁnd any reason to doubt about
their accuracy. One option is to conduct the parallel experi-
ments to test the AKR expression status in the liver cells both
in vitro and in vivo.
Lafﬁn and Petrash examined expression of AKR1B1 and
AKR1B10 across all major human cancer types using database
searching [48,49]. They found that AKR1B10 was signiﬁcantly
overexpressed in cancers of lung and liver, while AKR1B1 was
more broadly overexpressed in human cancers but with a gen-
erally lower magnitude. Abnormal expression of AKRlB10
was also detected in HuH7 cells and most HCC tissues. A
somewhat surprising result came from the quantitative data
for AKR1B10 mRNA and protein in other cancer cell lines.
In contrast to extremely high abundance of AKR1B10 mRNA
and protein in HuH7 cells, three other liver cancer lines,
HepG2, BEL7402 and SMMC7721, possessed almost normal
levels of AKR1B10 mRNA and protein. More impressively,
HuH7 cells showed global overexpression for most AKR
genes, indicating that AKR1B10 overexpression is not a un-
ique feature of tumorigenesis. Our data in quantitative mRNA
and protein of AKR1B10 therefore prompt two questions. Is
the HuH7 cell line more representative for liver cancer than
other cancer cell lines? Is the AKR1B10 protein more stable
in tissues or cells than other AKR members? No matter what
the answer would be, the use of AKR1B10 for diagnosis and
prognosis is of great potential interest and merits further inves-
tigation in the future.Gender Diﬀerentiation degree Morphology
– Immortalized Epithelial
Male Well-medium diﬀerentiated Epithelial
Male Well diﬀerentiated Epithelial
Male Medium–low diﬀerentiated Epithelial
Male Medium–low diﬀerentiated Epithelial
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Cell lines and tissues
L-02, BEL7402 and SMMC7721 cells were cultured in RPMI
1640 medium plus 10% FBS at 37 C with 5% CO2. HepG2
and HuH7 cells were cultured in DMEM medium plus 10%
FBS at 37 C with 5% CO2. L-02 is a relatively normal hepatic
cell line, while the others are HCC cell lines characterized by
various degrees of differentiation. HepG2 and HuH7 are
well-medium differentiated cell lines, while BEL7402 and
SMMC7721 are medium–low differentiated cell lines (Table 3).
Thirty two paired hepatic tissues of patients consisting of
the HCC portions with their corresponding adjacent tissues
and 10 unpaired ones were obtained from the Department of
Oncology, General Hospital of PLA. And 13 pairs of tissues
were gifts from Xiaohang Zhao’s lab in Cancer Institute and
Cancer Hospital, Chinese Academy of Medical Sciences and
Peking Union Medical College. Among them, 19 are well-dif-
ferentiated ones, 15 are medium-differentiated ones and 21 are
low-differentiated ones. The study was approved by the Re-
search Ethics Boards of General Hospital of PLA and Cancer
Institute and Cancer Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College. Informed consent
forms were obtained from all patients.
Quantitative real-time PCR analysis
Total RNAs were extracted from the ﬁve hepatic cell lines with
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reversely
transcribed to generate cDNA libraries using reverse transcrip-
tase M-MLV (Promega, Madison, WI, USA). Primers speciﬁc
for respective AKR genes were designed using PrimerQuest
software (IDT DNA, Coralville, IA, USA) and sequences of
primers were listed in Table S2. Transcript levels of AKRs in
the aforementioned hepatic cell lines were quantitatively eval-
uated using real-time PCR with an ABI PRISM 7300 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) and EvaGreen dye (OPE Tech, Shanghai, China). The
ﬁrst step of cycling was 5 min at 95 C followed by 40 cycles
of 95 C for 15 s, 60 C for 15 s, 72 C for 15 s and 80 C for
30 s, then 10 min at 72 C. The second step is dissociation
stage, 95 C for 15 s, 60 C for 15 s and 95 C for 15 s. Tripli-
cate cDNA template samples were ampliﬁed and analyzed. All
samples were tested three times. Identity of all the real-time
PCR products was veriﬁed by sequencing (Figure S1).
Cell harvest and protein extraction
The hepatic cells were harvested by trypsin treatment. After
rinsed with saline solution, cells were incubated with lysis buf-
fer containing 8 M urea, 4% CHAPS, 10 mM DTT, 1 mM
PMSF, 1 mM EDTA and 40 mM Tris–HCl (pH 8.5). After
centrifugation at 20,000g for 20 min at 4 C, the supernatant
was removed and used as protein sample for electrophoresis
on 12% SDS–PAGE gels.
Quantitative MRM analysis
Protein levels of AKRs in hepatic cell lines were quantiﬁed by
MRMwith QTRP 5500 (Applied Biosystems, Foster City, CA,USA) and unique peptides. MRM pilot software (Applied Bio-
systems) was used to design transitions of unique peptides. The
sequences of unique peptides and corresponding transitions
are listed in Table S1. We excised the bands at 34–42 KDa
(about molecular weight of AKRs) to reduce the complexity
of the samples. These samples were processed for trypsin diges-
tion, mTRAQ label and MRM analysis.
Antigen expression
PCR products were veriﬁed by sequencing analysis. To pro-
duce the recombinant proteins, AKR1C1–1C4 were ligated
into pET30a(+) vectors, while the others were ligated into
pET28a(+), all fused in frame with N-terminal 6· His. Plas-
mids containing respective AKR1 sequences were transformed
into Escherichia coli BL21(DE3) for protein expression. All the
recombinant proteins were produced and puriﬁed with the Ni-
NTA spin column as instructed by manufacturer (Qiagen,
Venlo, Netherlands), which were used as antigens in full length
or truncated fragments for antibody generation.
Generation and selection of monoclonal antibodies
BALB/c mice were used for immunization of the AKR recom-
binant proteins. After four times of immunization, the
splenocytes were isolated and fused with a hypoxanthin–
aminopterin–thymidine (HAT)-sensitive mouse myeloma cell
line, SP2/0-Ag14, using polyethylene glycol method [50].
Hybridomas producing speciﬁc monoclonal antibody to
AKRs were selected, ampliﬁed and then injected into enteroco-
elia of mice. Monoclonal antibody puriﬁcation was carried out
by afﬁnity chromatography method. Antibodies of IgG sub-
class were puriﬁed on Protein G beads while antibodies of
IgM and IgA subclasses were puriﬁed on Protein L beads [50].
ELISA experiments were designed to select the speciﬁc
monoclonal antibodies of AKRs (BPI, Beijing, China) to avoid
cross reaction between AKR members. Each well was coated
with 10 ng AKR recombinant proteins. Speciﬁc antibodies
should only recognize the corresponding antigen without any
signal from the other AKRs.
Immunoblotting
Dot blotting analysis was performed to validate speciﬁcities
and sensitivities of the respective monoclonal antibodies (Fig-
ure S2A). Protein concentration was determined by the Brad-
ford method (Bio-Rad, Hercules, CA, USA). Recombinant
AKR proteins were dotted on PVDF membranes (Millipore,
Billerica, MA, USA) with increasing amounts (1, 10, 100 and
1000 ng). Membranes were then blocked in 5% milk in 1·
Tris-buffered saline Tween (TBST) overnight at 4 C and incu-
bated with a speciﬁc primary antibody (listed below) in 5%
milk for 1 h at 37 C. Blots were washed in 1· TBST three
times before incubated with an anti mouse secondary antibody
conjugated with HRP (ZB2305, ZSGB-BIO, Beijing, China)
for 1 h at room temperature. Finally, blots were washed and
bands were visualized by the Image Quant ECL equipment
(GE healthcare, Piscataway, NJ, USA). Primary antibodies
against AKRs and the working concentrations are as follows:
AKR1A1 S65 (1:700); AKR1B1 S1 (1:700); AKR1B10 S2
(1:8000); AKR1C1/1C2 S29 (1:10,000); AKR1C3 S8
(1:7000); AKR1C4 S34 (1:1000) and AKR7A2 S3 (1:1000).
238 Genomics Proteomics Bioinformatics 11 (2013) 230–240In addition, speciﬁcities of the monoclonal antibodies were
also validated with Huh7 cell lysate following the standard
protocols using the aforementioned antibodies (Figure S2B).
IHC
The protein levels of AKRs in the HCC samples and adjacent
tissues from patients were examined using IHC. Brieﬂy, tissue
sections were mounted and baked at 65 C for 1–2 h. Sections
were deparafﬁnized with xylene and re-hydrated in graded eth-
anol. Antigen retrieval was performed with 10 mM sodium cit-
ric acid buffer (pH 6.0) at high pressure for 2.5 min.
Endogenous peroxidase activity was blocked by incubating
the tissue sections with 3% H2O2 for 15 min. Antibodies were
diluted with the blocking buffer and incubation in a moist
chamber at 4 C overnight. After washing, the slides were trea-
ted with ready to use secondary antibody (ZB2305) and incu-
bated at 37 C for 25 min, followed by rinses with PBS. DAB
substrate was added to the slides and incubated at room tem-
perature for less than 10 min. Tissue sections were counter-
stained lightly with hematoxylin. Slides were dehydrated and
sealed with neutral balsam for visualization by light micros-
copy. Primary antibodies against AKRs and the working con-
centrations are as follows: AKR1A1 S65 (1:500); AKR1B10 S2
(1:10,000); AKR1C1/1C2 S29 (1:10,000); AKR1C3 S8 (1:5000)
and AKR1C4 S34 (1:200). The staining was scored as negative
(if <5% cells were stained in a ﬁeld examined) or positive (if
P5% cells were stained in a ﬁeld examined) by pathologists
and research scientists independently.
Statistical analysis
Results are presented as the mean ± standard error. Statistical
signiﬁcance was set at P< 0.05. For real-time PCR, the Ct
values of housekeeping gene b-actin were adopted to normalize
the expression of AKRs. The comparison of mRNA levels be-
tween the cell lines was achieved on the basis of the relative
values of gene expression calculated by 244Ct method [51].
One-way ANOVA and 2-way ANOVA were used for statisti-
cal analysis. For MRM, t test was used to determine P values
between samples. And for IHC, statistical analysis was carried
out by Pearson v2 test.
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